Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. on October 25, 2018, regarding events that occurred on October 22, 2018. The filing discloses the election of a new director and associated compensatory arrangements. Note: The request metadata referenced "Palvella Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Pieris Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Matthew L. Sherman, M.D., to the Board of Directors as a Class III Director. His term expires at the 2020 annual meeting of stockholders. Dr. Sherman brings clinical development expertise in oncology, hematology, and pulmonary diseases from previous roles at Acceleron Pharma, Synta Pharmaceuticals, and Wyeth-Ayerst Research.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Dr. Sherman's election:
- Stock Option: Granted a non-statutory stock option to purchase up to 30,000 shares of common stock.
- Exercise Price: $4.46 per share (closing price on October 24, 2018).
- Vesting: Vests one year after the grant date, subject to continued service.
- Cash Retainer: Entitled to an annual cash retainer of $35,000.
- Indemnification: An indemnification agreement will be entered into to cover expenses, judgments, fines, and settlement amounts arising from his service.
The filing states there are no other arrangements or understandings regarding his appointment and no material interest transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the correct registrant name is Pieris Pharmaceuticals, Inc., not Palvella Therapeutics, Inc.
- Confirm the stock option exercise price of $4.46 aligns with the market price on October 24, 2018.
- Review the Company's 2018 Employee, Director and Consultant Equity Incentive Plan to ensure sufficient shares were available for the 30,000-share grant.
- Check the Company's prior filings for the standard form of the Director Indemnification Agreement referenced in the text.